Adaptyx announced $14M in additional seed financing to fund the development of a continuous health monitoring device that aims to track small molecules, electrolytes, hormones, drugs, and proteins

Co-Founder & CEO Vijit Sabnis describes the company's goal of taking the field from continuous glucose monitoring to capturing a wider range of human biochemistry, and the clinical benefits that could flow from that.